menu ☰
menu ˟

New drug application for flibanserin will be resubmitted to the FDA

12 Feb 2014
The company responsible for flibanserin, a drug for treatment of hypoactive sexual dysfunction disorder, or HSDD, in premenopausal women, announced it will resubmit a new drug application for FDA approval after initiation of requested phase 1 studies...

Click here to view the full article which appeared in Endocrinology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.